Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome

Area of Science:

• Oncology
• Radiation Oncology
• Hematology

Background:

• The role of adjuvant radiotherapy in aggressive diffuse large cell lymphoma (DLCL) with bulky nodal disease and stage IV is not well-defined.
• Bulky nodal disease (>10 cm) and stage IV are poor prognostic factors in DLCL.

Purpose of the Study:

• To evaluate the impact of adjuvant radiotherapy on event-free survival (EFS) and overall survival (OS) in DLCL patients with bulky nodal disease.
• To assess the safety and tolerability of adjuvant radiotherapy in this patient cohort.

Main Methods:

• A prospective, randomized controlled clinical trial involving 341 patients with aggressive DLCL and bulky nodal disease.
• Patients achieved complete response after intensive chemotherapy and were randomized to receive either involved-field radiotherapy (40 Gy) or no radiotherapy.
• Follow-up was extended to assess long-term outcomes.

Main Results:

• Five-year EFS was 82% in the radiotherapy group versus 55% in the control group (P < 0.001).
• Five-year OS was 87% in the radiotherapy group versus 66% in the control group (P < 0.01).
• Radiotherapy was well-tolerated with mild acute toxicity and no apparent late toxicity to date.

Conclusions:

• Adjuvant radiotherapy significantly improves EFS and OS in DLCL patients with bulky nodal disease and stage IV.
• The addition of radiotherapy likely increases the possibility of cure in these high-risk patients.
• Adjuvant radiotherapy should be considered a standard part of initial treatment for DLCL patients with these adverse prognostic factors.